We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Neurology

Journal Scan / Research · October 30, 2021

Onasemnogene Abeparvovec Gene Therapy Shows Benefit in Symptomatic Infantile-Onset SMA Type 1

The Lancet Neurology


Additional Info

The Lancet Neurology
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial
Lancet Neurol 2021 Oct 01;20(10)832-841, E Mercuri, F Muntoni, G Baranello, R Masson, O Boespflug-Tanguy, C Bruno, S Corti, A Daron, N Deconinck, L Servais, V Straub, H Ouyang, D Chand, S Tauscher-Wisniewski, N Mendonca, A Lavrov

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading